Weight loss drugs may significantly reduce need for knee replacement surgery

Weight-loss drugs may prevent thousands of knee replacements, study suggests

Study of 6.8 million patients: 3-year GLP-1 therapy (semaglutide/tirzepatide) reduces knee surgery risk by 5%, preventing 14,400 procedures/year in the US and 1,500 in the UK. Expanded clinical benefits broaden GLP-1 pharma opportunity and shift healthcare spending toward preventive care, with implications for payer budgets and biotech investment thesis.